MeiraGTx 2025 Revenue Surges to $81.4M, EPS Loss Narrows to $(1.42) in Official 10-K
MGTX sits 67% above its 52-week low of $4.55.
Summary
MeiraGTx Holdings plc officially reported its 2025 financial results in its 10-K filing, showing a significant revenue increase to $81.4 million, up from $33.3 million in 2024. This surge was primarily driven by a $75.0 million upfront license payment from Lilly. The company also narrowed its GAAP net loss per ordinary share to $(1.42) from $(2.12) in the prior year. While earlier news reports on March 26 had indicated a qualitative improvement in 2025 results, this filing provides the definitive, audited figures. The improved financial performance, largely due to strategic partnerships, is a positive development for the company. Investors will now focus on the company's ability to translate these licensing revenues into sustained operational improvements and further clinical pipeline advancements.
At the time of this announcement, MGTX was trading at $7.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $613.3M. The 52-week trading range was $4.55 to $9.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.